Free Trial
NASDAQ:NBRV

Nabriva Therapeutics (NBRV) Stock Price, News & Analysis

Nabriva Therapeutics logo
$0.0003
0.00 (0.00%)
(As of 10/30/2024 ET)

About Nabriva Therapeutics Stock (NASDAQ:NBRV)

Key Stats

Today's Range
$0.0003
$0.0003
50-Day Range
N/A
52-Week Range
$1.22
$8.45
Volume
282 shs
Average Volume
29,344 shs
Market Capitalization
$9,604.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Receive NBRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBRV Stock News Headlines

Nabriva Therapeutics plc (NBRVF)
$5k to $1.3m in just 3 trades
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Nabriva Therapeutics PLC NBRVF
NBRV - Nabriva Therapeutics plc
NBRV Nabriva Therapeutics plc
See More Headlines

NBRV Stock Analysis - Frequently Asked Questions

Nabriva Therapeutics' stock was trading at $0.0003 at the beginning of the year. Since then, NBRV stock has increased by 0.0% and is now trading at $0.0003.
View the best growth stocks for 2024 here
.

Nabriva Therapeutics plc (NASDAQ:NBRV) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative net margin of 148.11% and a negative trailing twelve-month return on equity of 365.53%.
Read the conference call transcript
.

Shares of Nabriva Therapeutics reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nabriva Therapeutics investors own include SCYNEXIS (SCYX), Vaxart (VXRT), VBI Vaccines (VBIV), Acasti Pharma (ACST), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
5/06/2021
Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NBRV
Employees
39
Year Founded
N/A

Profitability

Net Income
$-57,190,000.00
Net Margins
-148.11%
Pretax Margin
-144.78%

Debt

Sales & Book Value

Annual Sales
$35.59 million
Book Value
$0.10 per share

Miscellaneous

Free Float
31,493,000
Market Cap
$9,604.50
Optionable
Not Optionable
Beta
1.53

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:NBRV) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners